Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type
- 1 December 1990
- journal article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 39 (6) , 613-614
- https://doi.org/10.1007/bf00316110
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs.Proceedings of the National Academy of Sciences, 1988
- Characterization of the common genetic defect in humans deficient in debrisoquine metabolismNature, 1988
- GC and GC-MS procedures for simultaneous phenotyping with dextromethorphan and mephenytoinClinica Chimica Acta; International Journal of Clinical Chemistry, 1988
- The molecular mechanisms of two common polymorphisms of drug oxidation-evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidationXenobiotica, 1986
- Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquin hydroxylationClinical Pharmacology & Therapeutics, 1985
- Simultaneous determination of thioridazine and its S-oxidized and N-demethylated metabolites using high-performance liquid chromatography on radially compressed silicaJournal of Chromatography B: Biomedical Sciences and Applications, 1982
- Defective N-oxidation of sparteine in man: A new pharmacogenetic defectEuropean Journal of Clinical Pharmacology, 1979
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977